Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 11
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Panelists discuss genotype-directed treatment options for advanced HR+/HER2– disease, including PI3K/AKT/mTOR inhibitors and antibody-drug conjugates (ADCs), their use based on recent data, impressions of these regimens, and how the recent first-line approval of inavolisib in combination with palbociclib and fulvestrant for PI3K-mutated HR+/HER2– metastatic breast cancer may change the treatment paradigm.
DISCLAIMER: The correct PFS data is 15 months vs. 7.3 months, not 24 vs. 15 months as stated; 2) Time to chemotherapy data was not available at primary analysis; 3) The safety profile characterization was incomplete - the treatment showed a low discontinuation rate of only 6% due to adverse events, and the adverse events mentioned are not key safety findings in our studies.
Video content above is prompted by the following:
Dr. Bardia to Dr. Chan:What are the more genotype-directed options for advanced HR+/HER2–- disease (PI3K/AKT/mTOR inhibitors, ADCs, etc.)?
How, and for what patient populations, are these being used based on the most recent data? What are your impressions of each of these regimens?
Inavolisib – How might the recent first-line inavolisib approval change the treatment paradigm? (approved in combination with palbociclib and fulvestrant for patients withPI3K-mutated, HR+, HER2–- la /metastatic breast cancer mBC that whoprogress on or relapse within 12 months after completing adjuvant endocrine therapy)change the treatment paradigm?